Literature DB >> 23315217

The expression of moesin in astrocytoma: correlation with pathologic grade and poor clinical outcome.

Ming Wu1, Ding-Yang Liu, Xian-Rui Yuan, Qing Liu, Xin-Jun Jiang, Dun Yuan, Jun Huang, Xue-Jun Li, Zhi-Quan Yang.   

Abstract

Moesin, a member of the ERM family, acts as a linker between the actin cytoskeleton and the plasma membrane and plays a key role in the control of cell morphology, motility, adhesion and other processes of tumourigenesis. The expression pattern and clinical significance of moesin in astrocytoma remain unknown. In this study, we used RT-PCR to systematically investigate the expression of moesin in 49 astrocytomas of different pathological grade and 6 normal brain tissues. We found that the mRNA expression levels of moesin in astrocytomas were significantly higher in comparison with normal brain tissues. Furthermore, moesin up-regulation was correlated with pathological grade of astrocytomas. Subsequently, we tested 112 astrocytomas and 14 normal brain tissues by immunohistochemistry. Similar results were also confirmed. Univariate and multivariate survival analysis were used to determine the correlations of moesin expression with overall survival and progression-free survival. Our results showed the expression of moesin was strongly negatively correlated with the patient progression-free survival and overall survival. These results suggest moesin protein involved in the genesis and progression of astrocytomas and might be regarded as an independent predictor of poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23315217     DOI: 10.1007/s12032-012-0372-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  25 in total

1.  Human miR-31 targets radixin and inhibits migration and invasion of glioma cells.

Authors:  Dasong Hua; Dong Ding; Xu Han; Weiyi Zhang; Na Zhao; Gregory Foltz; Qing Lan; Qiang Huang; Biaoyang Lin
Journal:  Oncol Rep       Date:  2011-11-15       Impact factor: 3.906

2.  ERM stable knockdown by siRNA reduced in vitro migration and invasion of human SGC-7901 cells.

Authors:  Ming Ou-Yang; Hong-Rui Liu; Yu Zhang; XinGang Zhu; Qing Yang
Journal:  Biochimie       Date:  2011-02-23       Impact factor: 4.079

Review 3.  Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms.

Authors:  Martin H Pham; Gabriel Zada; Gina M Mosich; Thomas C Chen; Steven L Giannotta; Kai Wang; William J Mack
Journal:  Neurosurg Focus       Date:  2011-05       Impact factor: 4.047

4.  Moesin expression is associated with the estrogen receptor-negative breast cancer phenotype.

Authors:  C Carmeci; D A Thompson; W W Kuang; N Lightdale; H Furthmayr; R J Weigel
Journal:  Surgery       Date:  1998-08       Impact factor: 3.982

5.  The role of the membrane cytoskeleton cross-linker ezrin in medulloblastoma cells.

Authors:  Hirokatsu Osawa; Christian A Smith; Young Shin Ra; Paul Kongkham; James T Rutka
Journal:  Neuro Oncol       Date:  2008-12-16       Impact factor: 12.300

6.  Moesin functions antagonistically to the Rho pathway to maintain epithelial integrity.

Authors:  Olga Speck; Sarah C Hughes; Nicole K Noren; Rima M Kulikauskas; Richard G Fehon
Journal:  Nature       Date:  2003-01-02       Impact factor: 49.962

7.  Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators.

Authors:  Yanlin Yu; Javed Khan; Chand Khanna; Lee Helman; Paul S Meltzer; Glenn Merlino
Journal:  Nat Med       Date:  2004-01-04       Impact factor: 53.440

Review 8.  Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.

Authors:  F Lefranc; M Rynkowski; O DeWitte; R Kiss
Journal:  Adv Tech Stand Neurosurg       Date:  2009

9.  Moesin orchestrates cortical polarity of melanoma tumour cells to initiate 3D invasion.

Authors:  Ana Estecha; Lorena Sánchez-Martín; Amaya Puig-Kröger; Rubén A Bartolomé; Joaquín Teixidó; Rafael Samaniego; Paloma Sánchez-Mateos
Journal:  J Cell Sci       Date:  2009-09-01       Impact factor: 5.285

10.  The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells.

Authors:  Bruce E Elliott; Jalna A Meens; Sandip K SenGupta; Daniel Louvard; Monique Arpin
Journal:  Breast Cancer Res       Date:  2005-03-21       Impact factor: 6.466

View more
  6 in total

Review 1.  Proteomic Research on the Antitumor Properties of Medicinal Mushrooms.

Authors:  Boris Jakopovic; Nada Oršolić; Ivan Jakopovich
Journal:  Molecules       Date:  2021-11-05       Impact factor: 4.411

2.  Behavioral remodeling of normal and cancerous epithelial cell lines with differing invasion potential induced by substrate elastic modulus.

Authors:  Arian Ansardamavandi; Mohammad Tafazzoli-Shadpour; Mohammad Ali Shokrgozar
Journal:  Cell Adh Migr       Date:  2018-08-28       Impact factor: 3.405

3.  Lentinan dose dependence between immunoprophylaxis and promotion of the murine liver cancer.

Authors:  Ying Wang; Xue Han; Yan Dong Li; Yabing Wang; Shi Yang Zhao; Dong Jie Zhang; Yu Lu
Journal:  Oncotarget       Date:  2017-08-01

4.  High Moesin Expression Is a Predictor of Poor Prognosis of Breast Cancer: Evidence From a Systematic Review With Meta-Analysis.

Authors:  Xiaoli Hu; Yang Liu; Zhitong Bing; Qian Ye; Chengcheng Li
Journal:  Front Oncol       Date:  2021-11-26       Impact factor: 6.244

5.  Understanding cytoskeleton regulators in glioblastoma multiforme for therapy design.

Authors:  Samaneh Masoumi; Aditya Harisankar; Aileen Gracias; Fabian Bachinger; Temesgen Fufa; Gayathri Chandrasekar; Frank Gaunitz; Julian Walfridsson; Satish S Kitambi
Journal:  Drug Des Devel Ther       Date:  2016-09-12       Impact factor: 4.162

6.  A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer Database.

Authors:  Amrit L Pappula; Shayaan Rasheed; Golrokh Mirzaei; Ruben C Petreaca; Renee A Bouley
Journal:  Cancers (Basel)       Date:  2021-08-26       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.